RLMD vs URGN
RLMD: Relmada Therapeutics is a clinical-stage biotechnology company developing a pipeline of differentiated therapies, led by a sustained-release intravesical chemotherapy for bladder cancer and a neurosteroid for rare CNS disorders. URGN: UroGen Pharma leverages its proprietary reverse-thermal hydrogel technology to transform the treatment of urothelial cancers from invasive surgery to effective, non-surgical local therapy.
Side-by-side fundamentals
| Metric | RLMD | URGN | Edge |
|---|---|---|---|
| Price as of 2026-10-08 close | $3.17 | $36.98 | |
| Market cap | $338M | $1.8B | |
| Net margin FY2025, SEC XBRL | n/a | -139.8% | |
| Gross margin | +21.3% | +88.7% | URGN higher |
| Operating margin FY2025, SEC XBRL | n/a | -113.7% | |
| ROE FY2025, SEC XBRL | -66.3% | n/a | |
| ROA FY2025, SEC XBRL | -61.0% | -76.6% | RLMD higher |
| Debt / equity as of 2026-09-02 | 0.00 | 4.77 | RLMD lower |
| Revenue growth (YoY) as of 2026-09-02 | n/a | +100.3% | |
| Revenue CAGR (3y) SEC XBRL | n/a | +19.5% | |
| Dividend streak (yrs) SEC XBRL | 0 | 0 | Tie |
| Beta as of 2026-09-02 | 0.75 | 1.15 | |
| 1-year return as of 2026-10-08 close | +48.8% | +113.4% | URGN higher |
Fundamentals: SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-02 for the rest. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-10-08.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.